Amy A Kirkham1, Edith Pituskin1,2, Richard B Thompson1, John R Mackey1,2, Sheri L Koshman1,3, Davinder Jassal2,4,5, Marshall Pitz2,4,6, Mark J Haykowsky1, Joseph J Pagano1,3, Kelvin Chow3,7, Albert K Tsui1, Justin A Ezekowitz1,3, Gavin Y Oudit1,3, D Ian Paterson1,3. 1. University of Alberta, 8440 112 Street NW, Edmonton, Alberta, Canada, T6G 2R7. 2. Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada, T6G 1Z2. 3. Mazankowski Alberta Heart Institute, 11220 83 Avenue NW, Edmonton, Alberta, Canada, T6G 2B7. 4. University of Manitoba, 727 McDermot Avenue, Winnipeg, Manitoba, Canada, R3E 3P5. 5. St. Boniface Hospital, 409 Taché Avenue, Winnipeg, Manitoba, Canada, R2H 2A6. 6. CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba, Canada, R3E 0V9. 7. Cardiovascular MR R&D, Siemens Medical Solutions USA Inc., 737 N Michigan Avenue, Chicago, Illinois, USA, 60611.
Abstract
AIMS: An improved understanding of the pathophysiology of trastuzumab-mediated cardiotoxicity is required to improve outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We aimed to characterize the cardiac and cardiometabolic phenotype of trastuzumab-mediated toxicity and potential interactions with cardiac pharmacotherapy. METHODS AND RESULTS: This study was an analysis of serial magnetic resonance imaging (MRI) and circulating biomarker data acquired from patients with HER2-positive early-stage breast cancer participating in a randomized-controlled clinical trial for the pharmaco-prevention of trastuzumab-associated cardiotoxicity. Circulating biomarkers (B-type natriuretic peptide, troponin I, MMP-2 and -9, GDF-15, neuregulin-1, and IGF-1) and MRI of cardiac structure and function and abdominal fat distribution were acquired prior to trastuzumab, post-cycle 4 and post-cycle 17. Ninety-four participants (51 ± 8 years) completed the study with 30 on placebo, 33 on perindopril, and 31 on bisoprolol. Post-cycle 4, global longitudinal strain deteriorated from baseline in both placebo (+2.0 ± 2.7%, P = 0.002) and perindopril (+0.9 ± 2.5%, P = 0.04), but not with bisoprolol (-0.2 ± 2.1%, P = 0.55). In all groups combined, extracellular volume fraction and GDF-15 increased post-cycle 4 (+1.3 ± 4.4%, P = 0.004; +130 ± 150%, P ≤ 0.001, respectively). However, no significant change in troponin I was detected throughout trastuzumab. In all groups combined, visceral and intermuscular fat volume increased post-cycle 4 (+7 ± 17%, P = 0.02, +8 ± 23%, P = 0.02, respectively), while muscle volume and IGF-1 decreased from post-cycle 4 to 17 (-2 ± 10%, P = 0.008, -18 ± 28%, P < 0.001, respectively). CONCLUSION: Trastuzumab results in impaired cardiac function and early myocardial inflammation. Trastuzumab is also associated with deleterious changes to the cardiometabolic phenotype which may contribute to the increased cardiovascular risk in this population. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: An improved understanding of the pathophysiology of trastuzumab-mediated cardiotoxicity is required to improve outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We aimed to characterize the cardiac and cardiometabolic phenotype of trastuzumab-mediated toxicity and potential interactions with cardiac pharmacotherapy. METHODS AND RESULTS: This study was an analysis of serial magnetic resonance imaging (MRI) and circulating biomarker data acquired from patients with HER2-positive early-stage breast cancer participating in a randomized-controlled clinical trial for the pharmaco-prevention of trastuzumab-associated cardiotoxicity. Circulating biomarkers (B-type natriuretic peptide, troponin I, MMP-2 and -9, GDF-15, neuregulin-1, and IGF-1) and MRI of cardiac structure and function and abdominal fat distribution were acquired prior to trastuzumab, post-cycle 4 and post-cycle 17. Ninety-four participants (51 ± 8 years) completed the study with 30 on placebo, 33 on perindopril, and 31 on bisoprolol. Post-cycle 4, global longitudinal strain deteriorated from baseline in both placebo (+2.0 ± 2.7%, P = 0.002) and perindopril (+0.9 ± 2.5%, P = 0.04), but not with bisoprolol (-0.2 ± 2.1%, P = 0.55). In all groups combined, extracellular volume fraction and GDF-15 increased post-cycle 4 (+1.3 ± 4.4%, P = 0.004; +130 ± 150%, P ≤ 0.001, respectively). However, no significant change in troponin I was detected throughout trastuzumab. In all groups combined, visceral and intermuscular fat volume increased post-cycle 4 (+7 ± 17%, P = 0.02, +8 ± 23%, P = 0.02, respectively), while muscle volume and IGF-1 decreased from post-cycle 4 to 17 (-2 ± 10%, P = 0.008, -18 ± 28%, P < 0.001, respectively). CONCLUSION: Trastuzumab results in impaired cardiac function and early myocardial inflammation. Trastuzumab is also associated with deleterious changes to the cardiometabolic phenotype which may contribute to the increased cardiovascular risk in this population. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Elizabeth M Cespedes Feliciano; Wendy Y Chen; Patrick T Bradshaw; Carla M Prado; Stacey Alexeeff; Kathleen B Albers; Adrienne L Castillo; Bette J Caan Journal: J Clin Oncol Date: 2019-08-01 Impact factor: 44.544
Authors: Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti Journal: Eur Heart J Cardiovasc Imaging Date: 2014-10 Impact factor: 6.875
Authors: Anne Marij G Burgers; Nienke R Biermasz; Jan W Schoones; Alberto M Pereira; Andrew G Renehan; Marcel Zwahlen; Matthias Egger; Olaf M Dekkers Journal: J Clin Endocrinol Metab Date: 2011-07-27 Impact factor: 5.958
Authors: Ian J Neeland; Robert Ross; Jean-Pierre Després; Yuji Matsuzawa; Shizuya Yamashita; Iris Shai; Jaap Seidell; Paolo Magni; Raul D Santos; Benoit Arsenault; Ada Cuevas; Frank B Hu; Bruce Griffin; Alberto Zambon; Philip Barter; Jean-Charles Fruchart; Robert H Eckel Journal: Lancet Diabetes Endocrinol Date: 2019-07-10 Impact factor: 32.069
Authors: Bonnie Ky; Mary Putt; Heloisa Sawaya; Benjamin French; James L Januzzi; Igal A Sebag; Juan Carlos Plana; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: J Am Coll Cardiol Date: 2013-11-27 Impact factor: 24.094
Authors: Biniyam G Demissei; Rebecca A Hubbard; Liyong Zhang; Amanda M Smith; Karyn Sheline; Caitlin McDonald; Vivek Narayan; Susan M Domchek; Angela DeMichele; Payal Shah; Amy S Clark; Kevin Fox; Jennifer Matro; Angela R Bradbury; Hayley Knollman; Kelly D Getz; Saro H Armenian; James L Januzzi; W H Wilson Tang; Peter Liu; Bonnie Ky Journal: J Am Heart Assoc Date: 2020-01-21 Impact factor: 5.501
Authors: Amy A Kirkham; Katherine L Ford; Jordan Topolnyski; Bruna Ramos Da Silva; D Ian Paterson; Carla M Prado; Anil A Joy; Normand G Boulé; Edith Pituskin; Mark J Haykowsky; Richard B Thompson Journal: JACC CardioOncol Date: 2022-05-17
Authors: Waleed Alhumaid; Stephanie D Small; Amy A Kirkham; Harald Becher; Edith Pituskin; Carla M Prado; Richard B Thompson; Mark J Haykowsky; D Ian Paterson Journal: Front Cardiovasc Med Date: 2022-02-21
Authors: Amy A Kirkham; Edith Pituskin; John R Mackey; Justin G Grenier; D Ian Paterson; Mark J Haykowsky; Richard B Thompson Journal: Oncologist Date: 2022-09-02 Impact factor: 5.837